Direct Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery: A Pilot Randomized Controlled Trial

Read full text Summarise with VIRAT
Authors: Erica H. Z. Wang, Ricky D. Turgeon, Eric Chu, Terri Sun, Jamil G. Bashir, Defen Peng, Richard Cook, Juliet Ann Atherstone, Tracy Gwozd, Jian Ye
Cited by: 0
References: 35

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background To conduct a pilot randomized controlled trial (RCT) of direct oral anticoagulants (DOACs) early after cardiac surgery to determine the feasibility of a larger RCT. Methods We conducted an open-label, two-site, pilot RCT of adults undergoing cardiac surgery with an indication for anticoagulation, excluding mechanical valves and bioprosthetic mitral valve replacements. We randomized patients 1:1 to DOAC or warfarin started during the index hospitalization with a standardized time of post-operative initiation and bridging for high thrombosis risk. The coprimary feasibility outcome goals were recruitment of ≥70% eligible patients and adherence to the anticoagulation protocol in ≥80% patients. The primary clinical composite outcome included all-cause mortality, major bleeding, stroke, systemic embolism, or pericardial effusion requiring intervention within 3 months. Results Between October 2022 and February 2024, 547 patients were screened, 163 met inclusion criteria, 104 were randomized, and 100 were analyzed (50 in each group). Median age was 72 years, 22% were female, 54% had pre-existing atrial fibrillation, 37% had post-operative atrial fibrillation, with median CHA 2 DS 2 -VASc 3 and HAS-BLED 2. We recruited 64% of eligible patients and anticoagulation protocol adherence was 91%. The clinical composite outcome occurred in 8% with DOAC (2 major bleeding, 1 pericardial effusion, 1 death) vs 4% with warfarin (2 strokes); log-rank p=0.42. Conclusions : Although the a priori recruitment goal was not met, this trial supports the need for and gains valuable insights into key challenges to mitigate, which guides the design of a large, definitive multicenter RCT comparing DOACs versus warfarin in cardiac surgery patients.

Fields of Study & Subjects

Atrial Fibrillation Management and Outcomes Venous Thromboembolism Diagnosis and Management Cardiac Valve Diseases and Treatments

Publication details

Journal / source
CJC Open
Volume
8
Issue
8
Pages
1109–1118
Publication date
28 March 2026
Language
EN